PUBLIC COMPANY
save$ARQTArcutis Biotherapeutics, Inc.
$ARQT25.35-4.20%Westlake Village, CA, USupdated 8h ago
community read0 votes
pipeline
2
marketed
1
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Marketed1pre_registration
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
- phase1Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
- phase3Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
- phase3Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)
- phase2Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis
- phase3Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)
- phase3Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
- phase3Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 1, 26SELLWelgus Howard G.· −$239K↗
- Mar 2, 26SELLLeonard Keith R· director−$997K↗
- Mar 2, 26SELLWatanabe Todd· See Remarks−$913K↗
- Mar 2, 26SELLWelgus Howard G.· −$257K↗
- Mar 2, 26SELLMatsuda Masaru· See Remarks−$165K↗
- Mar 2, 26SELLBurnett Patrick· See Remarks−$154K↗
- Mar 2, 26SELLEdwards Larry Todd· See Remarks−$90K↗
- Mar 2, 26SELLVairavan Latha· SVP Chief Financial Officer−$70K↗
- Mar 2, 26SELLMatsuda Masaru· See Remarks−$51K↗
- Mar 2, 26SELLWatanabe Todd· See Remarks−$28K↗
- Mar 2, 26SELLMatsuda Masaru· See Remarks−$5K↗
- Mar 2, 26SELLBurnett Patrick· See Remarks−$5K↗
- Mar 2, 26SELLEdwards Larry Todd· See Remarks−$3K↗
- Mar 2, 26SELLVairavan Latha· SVP Chief Financial Officer−$2K↗
- Feb 27, 26SELLMatsuda Masaru· See Remarks−$93K↗
routine RSU / option mechanics (5)
- Mar 2, 26option exerciseLeonard Keith R · director27,052 sh
- Mar 2, 26option exerciseLeonard Keith R · director12,220 sh
- Mar 2, 26option exerciseLeonard Keith R · director27,052 sh
- Mar 2, 26option exerciseLeonard Keith R · director12,220 sh
- Feb 27, 26grantBurnett Patrick · See Remarks77,000 sh
🐶 Hiring Signal
next earnings Oct 27, 2026
News
no news has mentioned this company yet
Data sources
last refreshed 18m ago
Found something off?
comments(0)
5-min edit window · permanent after that